New results from the OPENCORONA Phase 1 clinical study of a COVID‑19 vaccine candidate have now been published in Molecular Therapy Advances.
The study represents an international research collaboration focused on the evaluation of a novel multi‑antigen SARS‑CoV‑2 DNA vaccine and contributes new data from an early clinical development phase.
Ola Tuvesson and Eva‑Karin Gidlund from NorthX Biologics have contributed to the study, and are listed as co‑authors on the publication. Their involvement reflects NorthX Biologics’ role in supporting advanced biologics research through development, manufacturing expertise, and collaboration with academic and industrial partners.
The participation in OPENCORONA Phase 1 clinical study further highlights NorthX Biologics’ engagement in early‑stage clinical programs and its experience in working with complex biological products within regulated development frameworks. Contributing to peer‑reviewed publications is an important part of translating scientific and technical work into shared knowledge for the broader life science community.
🔗 Read the full article here:
A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations
Stay updated with the latest NorthX Biologics news, events and insights by subscribing to our newsletter.
